Baseline values and short serial Change: A "road map" for a poor early outcome in idiopathic pulmonary fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 184, Issue 4, 2011, Pages 395-397

  Wells, Athol U ^a   Richards, Thomas J ^b   Martinez, Fernando J ^c  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO;

COMORBIDITY; DISEASE COURSE; DISEASE SEVERITY; EDITORIAL; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION;

FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE;

EID: 80051815528     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201107-1216ED     Document Type: Editorial

References (15)

1. Latsi P.I., du Bois R.M., Nicholson A.G., Colby T.V., Bisirtzoglou D., Nikolakopoulou A., Veeraraghavan S., Hansell D.M.,Wells A.U. Fibrotic idiopathic interstitial pneumonia: The prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003;168:531-537. (Pubitemid 37088594)
2. Collard H.R., King T.E. Jr, Bartelson B.B., Vourlekis J.S., Schwarz M.I., Brown K.K. Changes in clinical and physiologic variables predict survival in Idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:538-542. (Pubitemid 37088595)
3. Flaherty K.R., Mumford J.A., Murray S., Kazerooni E.A., Gross B.H., Colby T.V., Travis W.D., Flint A., Toews G.B., Lynch J.P. III, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168: 543-548. (Pubitemid 37088596)
4. Martinez F.J., Safrin S., Weycker D., Starko K.M., Bradford W.Z., King T.E. Jr, Flaherty K.R., Schwartz D.A., Noble P.W., Raghu G., et al. The clinical course of subjects with idiopathic pulmonary fibrosis. Ann Intern Med 2005;142:693-697.
5. Raghu G., Brown K.K., Bradford W.Z., Starko K., Noble P.W., Schwartz D.A., King T.E. Jr, Idiopathic Pulmonary Fibrosis Study Group. A placebocontrolled trial of interferon gamma-1b in subjects with idiopathic pulmonary fibrosis. N Engl J Med 2004;350:125-133. (Pubitemid 38056223)
6. Demedts M., Behr J., Buhl R., Costabel U., Dekhuijzen R., Jansen H.M., MacNee W., Thomeer M., Wallaert B., Laurent F., et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353:2229-2242. (Pubitemid 41697286)
7. du Bois R.M., Weycker D., Albera C., Bradford W.Z., Costabel U., Kartashov A., et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:459-466.
8. King Te Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, et al. Effect of interferon gamma-1b om survival in patients with idiopathic pulmonary fibrosis (INSPIRE): A multicentre randomised placebo-controlled trial. Lancet 2009;374:222-228.
9. Selman M., Carrillo G., Estrada A.,Mejia M., Becerril C., Cisneros J., Gaxiola M., Pérez-Padilla R., Navarro C., Richards T., et al. Accelerated variant of idiopathic pulmonary fibrosis: Clinical behavior and gene expression pattern. PLoS One 2007;2:e482.
10. Boon K., Bailey N.W., Yang J., Steel M.P., Groshong S., Kervitsky D., Brown K.K., Schwarz M.I., Schwartz D.A. Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF). PLoS One 2009;4:e5134.
11. du Bois R.M., Weycker D., Albera C., Bradford W.Z., Costabel U., Kartashov A., Lancaster L., Noble P.W., Sahn S.A., Szwarcberg J., et al. Six-minute-walk test in diopathic pulmonary fibrosis: Test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011;183:1231-1237.
12. Wells A.U., King A.D., Rubens M.B., Cramer D., du Bois R.M., Hansell D.M., Lone C.F.A. a functional-morphological correlation based on extent of disease on thin-section computed tomography. Am J Respir Crit Care Med 1997;155:1367-1375. (Pubitemid 27172785)
13. Schmidt S.L., Nambiar A.M., Tayob N., Sundaram B., Han M.K., Gross B.H., Kazerooni E.A., Chugtai A.R., Lagstein A., Myers J.L., et al. Pulmonary function measures predict mortality differently in idiopathic pulmonary fibrosis versus combined pulmonary fibrosis and emphysema. Eur Respir J 2011;38:176-183.
14. Zappala C.J., Latsi P.I., Nicholson A.G., Colby T.V., Cramer D., Renzoni E.A., Hansell D.M., du Bois R.M., Wells A.U. Marginal decline in FVC is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:830-836.
15. Raghu G., Collard H.R., Egan J.J., Martinez F.J., Behr J., Brown K.K., Colby T.V., Cordier J.F., Flaherty K.R., Lasky J.A., et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: Idiopathic pulmonary fibrosisEvidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;83:788-824.